FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Machinaton	$ \sim $	20E40	
Washington,	D.C.	20349	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHI

OMB APPROVAL											
OMB Number: 3235-											
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Brannelly Paul					<u>C</u>	2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC [COLL]									5. Relationship of Reporti (Check all applicable) Director Officer (give title			10% Own		
	LLEGIUM	First) PHARMACEUT Y CENTER DRI		2.		3. Date of Earliest Transaction (Month/Day/Year) 01/19/2021									below)		Presid	below) dent & CF	`	
(Street) STOUGHTON MA 02072					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi Line) X							
(City)	(5	State)	(Zip)																	
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Tran Date (Month				sactio	1			3. 4. Securiti Disposed Code (Instr.			ties Acqui	red (A)	or	5. Amoun Securities Beneficial Owned Fo	Forn ly (D) c		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) (D)	or P	rice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 01/1				9/20	/2021			A		42,000(1)		1	\$ <mark>0</mark>	215,758		D				
Common Stock 01/19				9/20)/2021			A		8,161 A		(2)	223,919			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye		l. Transa Code (I		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercise Expiration Date (Month/Day/Yea		of Securitie		ties 1g e Secu		B. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
				С	Code	v	(A)		Date Exercisabl		xpiration ate	Title	Amo or Num of Sh			Transacti (Instr. 4)	on(s)			
Stock Option (Right to Purchase)	\$24.06	01/19/2021			A		120,000		(3)	0	1/19/2031	Common Stock	120	0,000 \$0 120,000		00	D			

Explanation of Responses:

- 1. Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.
- 2. On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 8,161 performance share units granted in two prior
- 3. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2022, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer

Remarks:

/s/ Paul Brannelly

01/21/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.